Takaaki Mizuno, CEO of CLINIAL CO., LTD., is scheduled to present at the 64th Annual Meeting of the Japan Society of Clinical Oncology (JSCO2026). His presentation has also been selected for the Young Oncologist Award (YOA).
On October 22, 2026, he will present “A Pan-Cancer Analysis of Clinically Actionable Genomic Alterations Not Covered by Drug-Specific Companion Diagnostics” in General Oral Session 3, “Medical DX.”
The presentation will examine differences between the variants covered by drug-specific companion diagnostics and those identified by comprehensive genomic profiling (CGP), using cancer genomic data collected across multiple institutions in Japan. It will explore how the choice of testing method may affect the identification of potential candidates for targeted therapies, and discuss testing strategies that account for the genomic alterations observed in each cancer type.
This work reflects CLINIAL’s approach to organizing and analyzing healthcare data to inform clinical care and drug development. By combining genomic and clinical information, CLINIAL aims to clarify the patient populations that may need treatment, support medical institutions in considering treatment options, and help pharmaceutical companies identify potential trial candidates and assess trial feasibility. Through these efforts, we aim to improve access to new treatments.
Presentation details
- Meeting: 64th Annual Meeting of the Japan Society of Clinical Oncology (JSCO2026)
- Date: Thursday, October 22, 2026
- Session: General Oral Session 3, “Medical DX”
- Session time: 10:40 to 11:30 (JST)
- Venue: Room 12, Kobe International Conference Center, 5F, Room 501
- Presentation number: O3-2
- Title: A Pan-Cancer Analysis of Clinically Actionable Genomic Alterations Not Covered by Drug-Specific Companion Diagnostics
- Presenter: Takaaki Mizuno
- Affiliations: Center for Cancer Genomics, Keio University School of Medicine / CLINIAL CO., LTD.
Please see the official meeting website and program for details.
(References)